Friday, 29 March 2024


Aptose inks license agreement with CrystalGenomics

18 June 2018 | News

Under the agreement, CrystalGenomics will receive an upfront payment of $3 million and is eligible for development, regulatory and commercial-based milestones.

Image credit- bnpparibasmf.in

Image credit- bnpparibasmf.in

Aptose Biosciences Inc., a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, has entered into a license agreement with CrystalGenomics, Inc. for China rights to CG-806 (including People’s Republic of China, Hong Kong and Macau). Aptose will now own worldwide rights (excluding Korea) to develop and commercialize CG-806, a first-in-class, highly potent oral small molecule being developed for acute myeloid leukemia (AML), B-cell malignancies and other hematologic malignancies.

Under the agreement, CrystalGenomics will receive an upfront payment of $3 million and is eligible for development, regulatory and commercial-based milestones, as well as single-digit royalties on product sales in China. Total deal value for the China territory, including the upfront payment, is up to $125 million.

Recently Aptose exercised its option to obtain the exclusive license from CrystalGenomics to develop and commercialize CG-806 worldwide outside of China and  Korea.  This new agreement extends that license agreement to include China.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account